| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELANE |
| Uniprot No | P08246 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-267aa |
| 氨基酸序列 | IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQRSEDNPCPHPRDPDPASRTH |
| 预测分子量 | 25.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ELANE重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅供示例参考)：
---
1. **标题**: "High-Yield Expression and Purification of Recombinant Human Neutrophil Elastase for Inflammatory Disease Modeling"
**作者**: Zhang L, et al.
**摘要**: 研究报道在大肠杆菌系统中成功表达可溶性重组ELANE蛋白，通过亲和层析纯化，并证实其在体外水解弹性蛋白的活性。进一步在小鼠急性肺损伤模型中验证了其促炎作用。
2. **标题**: "Structural Insights into Recombinant ELANE Protease: Implications for Substrate Specificity"
**作者**: Thompson R, et al.
**摘要**: 通过X射线晶体学解析了重组ELANE的三维结构，揭示了活性位点的关键氨基酸残基，并利用突变实验阐明了其底物选择性的分子机制。
3. **标题**: "Functional Rescue of ELANE Mutants by Recombinant Protein Delivery in Neutropenia Models"
**作者**: Rao S, et al.
**摘要**: 在HEK293细胞中表达功能性重组ELANE蛋白，证明其能够恢复先天性中性粒细胞减少症患者细胞的蛋白酶活性，为基因治疗提供了实验依据。
4. **标题**: "Development of a Fluorescence-Based Assay for Recombinant ELANE Activity Screening"
**作者**: Kim J, et al.
**摘要**: 开发了一种基于荧光底物的重组ELANE酶活检测方法，用于高通量筛选抑制剂，并在慢性阻塞性肺病(COPD)相关模型中验证其应用潜力。
---
**建议**：如需真实文献，请通过PubMed或Google Scholar搜索关键词“recombinant ELANE protein”、“neutrophil elastase expression”等，并筛选近年发表的研究。
ELANE recombinant protein is derived from the human ELANE gene, which encodes neutrophil elastase, a serine protease predominantly expressed in neutrophils. This enzyme plays a critical role in innate immunity by degrading pathogenic proteins and regulating inflammatory responses. Structurally, ELANE consists of a single polypeptide chain (~29-34 kDa) with a catalytic triad (His57. Asp102. Ser195) essential for enzymatic activity. Its primary function includes breaking down extracellular matrix components and bacterial cell walls, but dysregulation is linked to tissue damage in conditions like chronic obstructive pulmonary disease (COPD) and acute lung injury.
Recombinant ELANE is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, ensuring high purity and bioactivity. Researchers employ it to study neutrophil-mediated inflammation, protease-antiprotease imbalances, and genetic disorders like cyclic neutropenia or severe congenital neutropenia (SCN), where ELANE mutations disrupt neutrophil maturation. It also serves as a tool for drug screening, particularly for inhibitors targeting excessive elastase activity in inflammatory diseases.
Therapeutically, recombinant ELANE has potential in replacement therapy for deficiency states or as a target for neutralizing antibodies in pathologies driven by protease hyperactivity. However, challenges remain in balancing its beneficial and detrimental effects, optimizing delivery methods, and ensuring stability *in vivo*. Current studies focus on engineering variants with modulated activity or improved pharmacokinetics. Understanding ELANE's dual roles in immunity and tissue homeostasis continues to be vital for developing targeted treatments in inflammatory and genetic disorders.
×
